Markets:

Overview

News

Currencies

International

Treasuries

Fortrea Holdings Inc. - Common Stock (NQ:FTRE)

9.070 -0.480 (-5.03%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fortrea Holdings Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

April 03, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

March 26, 2025

From Pomerantz LLP

Via GlobeNewswire

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

March 26, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest...

Via StockStory

Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the Firm

March 25, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks

March 25, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers.

Via StockStory

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

March 21, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

March 20, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 20, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

March 19, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

FORTREA ALERT: Bragar Eagel & Squire, P.C. is Investigating Fortrea Holdings Inc. on Behalf of Fortrea Stockholders and Encourages Investors to Contact the Firm

March 18, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)

March 18, 2025

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.

Via StockStory

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

March 17, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

Via StockStory

Topics Artificial Intelligence

Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,...

Via StockStory

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

March 12, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.

Via StockStory

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

March 11, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...

Via StockStory

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

March 05, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 05, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4

March 05, 2025

Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.

Via StockStory

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

March 04, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? ↗

March 03, 2025

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...

Via Benzinga

Why Fortrea (FTRE) Shares Are Plunging Today

March 03, 2025

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company delivered weak fourth-quarter 2024 results, with sales, operating profits, and...

Via StockStory

Fortrea (NASDAQ:FTRE) Misses Q4 Revenue Estimates, Stock Drops

March 03, 2025

Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 1.8% year on year to $697 million. The company’s full-year revenue...

Via StockStory

Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance

March 03, 2025

From Fortrea Holdings Inc

Via GlobeNewswire

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

What To Expect From Fortrea’s (FTRE) Q4 Earnings

March 02, 2025

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know.

Via StockStory

Fortrea to Add Erin L. Russell to Board of Directors

February 21, 2025

Fortrea and Starboard enter into Cooperation Agreement

From Fortrea Holdings Inc

Via GlobeNewswire

1 Healthcare Stock to Hold Forever and 2 to Ignore

February 21, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

February 20, 2025

Fortrea to Sponsor SCRS’ Collaborate Forward Working Group, Encouraging Collaboration for More Efficient Clinical Trials

From Fortrea Holdings Inc

Via GlobeNewswire

Fortrea Announces Date for Fourth Quarter and Full Year 2024 Financial Results and Conference Call

January 30, 2025

From Fortrea Holdings Inc

Via GlobeNewswire

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.